突破性藥物傳輸系統瞄準腦癌
Breakthrough Drug Delivery System Targets Brain Cancer
Updated at: June 9, 2026 at 01:45 AM
治療惡性腦腫瘤，如膠質母細胞瘤，長期以來一直是醫學上的重大挑戰，主要是因為血腦屏障（BBB）的存在。
Treating malignant brain tumors like glioblastoma has long been a major medical challenge, primarily due to the blood-brain barrier (BBB).
這個保護性的生理防線阻擋了超過98%的治療藥物進入大腦，導致許多傳統療法失效。
This protective physiological border blocks over 98% of therapeutic drugs from reaching the brain, rendering many conventional treatments ineffective.
然而，一項重大的技術轉變正在進行：開發旨在繞過或穿透該屏障的先進藥物輸送系統。
However, a significant technological shift is underway: the development of advanced drug delivery systems designed to bypass or penetrate this barrier.
研究人員目前正利用奈米技術，例如專門的奈米顆粒和脂質體，來提高藥物的穩定性和精確度。
Researchers are now using nanotechnology, such as specialized nanoparticles and liposomes, to improve drug stability and precision.
這些微觀載體經由工程設計，能專一性地標靶腫瘤受體，並僅在到達癌症部位的酸性環境時才釋放其「負載」。
These microscopic carriers are engineered to target tumor receptors specifically and release their 'payloads' only upon reaching the acidic environment of the cancer site.
除了系統性輸送外，醫師也正在使用可植入、可生物降解的晶片，將藥物直接釋放到切除腫瘤後的部位。
Beyond systemic delivery, doctors are also utilizing implantable, biodegradable wafers that release medication directly into the site of a removed tumor.
這些系統變得越來越靈活，不僅能攜帶化療藥物，還能攜帶如CRISPR等基因編輯工具及免疫療法藥劑。
These systems are becoming increasingly versatile, capable of carrying not only chemotherapy but also gene-editing tools like CRISPR and immunotherapies.
儘管腫瘤異質性與製造規模化等挑戰依然存在，這些精準標靶平台代表了充滿希望的未來。
While challenges such as tumor heterogeneity and manufacturing scalability remain, these precision-targeted platforms represent a hopeful future.
透過從粗糙的系統性治療轉向智慧型、刺激響應式的輸送，醫學正越來越接近有效深入腦癌核心的目標。
By moving away from blunt, systemic treatments toward intelligent, stimuli-responsive delivery, medicine is getting closer to effectively reaching the heart of brain cancer.
